Articles tagged with Squamous Cell Lung Cancer
Researchers at Ohio State University are testing psilocybin-assisted therapy to reduce depression and emotional distress in patients with advanced lung cancer. The trial aims to determine whether this approach can address the unique psychological challenges faced by lung cancer patients.
A new preclinical study shows that combining HER3-DXd with olaparib significantly improves treatment responses in lung cancer models. The combination therapy induces irreparable DNA damage in cancer cells and stimulates the immune system to combat the disease.
Researchers developed a simple, fast, and low-cost blood test that identifies the tumor's biological fingerprint with over 90% accuracy. The test distinguishes between lung cancer patients and healthy individuals without DNA sequencing.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found significant sex-based protein differences in lung adenocarcinoma, with 901 proteins varying between male and female patient samples. This study contributes to understanding cancer biology and may benefit physicians and patients.
A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...
A new nanodrug called Nano-273 could offer improved survival for patients with pancreatic and lung cancers by activating the immune system and blocking tumor growth. The drug, developed by University of Houston researcher Wei Gao, has shown promising results in early studies.
A new study may transform the diagnosis of Britain's number one cancer, lung cancer. Researchers are investigating whether low-dose CT scans can detect lung cancers earlier than current chest X-rays. The study aims to identify which patients would benefit from these more accurate scans.
A recent study has identified the 'cell of origin' of lung squamous cell carcinoma (LUSC), a second most common type of lung cancer among smokers. The research found that basal cells expressing the gene Krt5 become dominant in the trachea and eventually invade large areas of the lung, forming tumors.
The American College of Chest Physicians' CHEST Critical Care and CHEST Pulmonary journals have been indexed in Elsevier's Scopus database. This achievement is a testament to the high-quality research published in these journals, which provide open access content in pulmonary and critical care medicine.
A multicenter retrospective cohort study found that postoperative adjuvant radiotherapy improves overall survival in pN2 NSCLC patients, particularly with examined lymph nodes <10 and a lymph node ratio ≤0.2 or ≥0.53. These findings suggest that ELNs and LNR are valuable for identifying patients who may benefit from PORT.
Researchers investigated the use of CYFRA 21-1 and CXCR1/2 levels for detecting recurrence in stage III SCLC. The study found that a combined model can detect recurrence with high accuracy, and adjusting treatment regimens based on these values may improve patient outcomes.
Researchers have identified a novel protein FOXF1 that stabilizes blood vessels inside lung tumors, decreasing intertumoral hypoxia and preventing lung cancer metastases. Increasing levels of FOXF1 or FZD4 shows promise to improve therapeutic outcomes in lung cancer patients.
A new study from Umeå University found that lung cancer rates haven't decreased as expected with reduced smoking. Despite declining smoking rates, the number of cases of lung cancer has increased, especially among women. The study suggests that previous assumptions about the quick decrease in risk after quitting may have been exaggerated.
A new study reveals a link between the removal of the FGFR1 protein's extracellular domain and a significant decrease in tumour volume. This finding offers a potential new avenue of treatment for patients with squamous cell carcinoma of the lungs, who have shown limited success with current therapies.
Researchers found that a combination of AXL and EGFR inhibitors can suppress tumor growth and prevent relapse in patients with certain cancers. The study clarifies the novel regulatory mechanism by which AXL stimulates YAP via the EGFR-LATS1/2 axis.
A new study of over 200 people with premature aging syndromes caused by abnormally short telomeres suggests that chromosomal instability may not be the reason for increased cancer risk. Instead, immune system cells that age and die prematurely may play a role in cancer predisposition.
Researchers identify the minimum contribution of TACC3 for FGFR3-TACC3 fusion protein activation, revealing a novel target for treating FGFR translocation-driven cancers. The study shows that clinically identified FGFR3-TACC3 fusion proteins differ in biological activity depending on specific breakpoints.
Researchers at NYU Langone Health have identified a gene that drives development of lung squamous carcinoma, a common type of lung cancer. Deleting this gene causes normal cells to transform into cancerous cells, providing potential targets for new therapies.
Researchers identified molecular profiles of tumor matrices around squamous cell lung cancers, finding that altered matrices promote tumour growth and chemotherapy resistance. The study sheds light on why some patients progress well and others don't, and how personalized treatment can be developed.
A new study reveals that smoking is the main cause of preventable cancer and death in England, with socio-economic disparities in cancer incidence attributed to smoking prevalence. If everyone had the same smoking prevalence as the least deprived quintile, over 5,000 cases per year could have been prevented.
Researchers at ChristianaCare's Gene Editing Institute describe a new process for evaluating the impacts of gene edits that alter rather than completely disabling DNA code. The study validates the safety and efficacy of their novel approach for using CRISPR to improve lung cancer treatments.
Researchers at Moffitt Cancer Center have identified ΔNp63 as a protein that contributes to lung cancer development by regulating stem cells and crucial elements known as enhancers. The study found that mice deficient for ΔNp63 in the lung developed fewer lung tumors and had fewer stem cells compared to control mice.
A recent study by NTU Singapore has found a strong link between increasing air pollution and the rise of lung adenocarcinoma, a type of cancer. The study also discovered that declining smoking rates are associated with lower incidence of lung squamous cell carcinoma.
A comprehensive molecular map of lung squamous cell carcinoma has identified potential new drug targets, including the gene NSD3, and highlighted immune regulation pathways that could help cancer evade immunotherapies. The study's findings have also revealed metabolic dysregulation and crosstalk between different cellular processes.
The study finds that high miR-708 expression is associated with survival rates in lung squamous cell carcinoma patients. Additionally, miR-708 decreases proliferation, survival, and migration of lung cancer cells by inhibiting PGE2 signaling.
A case series reports 5 patients developing type 1 diabetes after receiving immunotherapy, with rapid onset and serious risk for diabetic ketoacidosis. Monitoring glycemia does not predict diabetes occurrence, and GAD antibodies are present in half of these cases, warranting further investigation.
Scientists at UNC Lineberger Comprehensive Cancer Center have identified CDR1as, a circular RNA, as a key player in driving metastasis in lung squamous cell cancer. By targeting this molecule, researchers believe it may be possible to develop new treatments with fewer side effects.
The study found that all tested tyrosine kinase inhibitors increased COX-2 expression in at least one of the tested cell lines in vitro. Fluorocoxib A uptake correlated with COX-2 expression detected by immunohistochemistry and Western blot analysis in xenografts in vivo.
A clinical trial led by CNIO's Luis Paz-Ares showed that immunotherapy significantly increases patient survival when administered alongside conventional chemotherapy. This opens the door to investigate its effectiveness in early stages of the disease.
A study published in Cell Reports has identified Np63a as a driver of squamous cell carcinoma growth and found that activating tumor suppressor genes TGFB2 and RHOA can halt this process. This discovery provides a promising pathway for developing new cancer treatments.
A new biomarker, CKAP4, has been identified in patients with stage I lung cancer, offering a potential non-invasive diagnostic marker that could improve patient outcomes. The sensitivity of serum CKAP4 was found to be higher than current sero-diagnostic markers.
A retrospective analysis of 73 lung squamous cell carcinoma patients found that higher body mass index and younger age were linked with longer progression-free survival. Patients with a better response to treatment also had longer overall survival.
Researchers found that squamous cell carcinoma is remarkably dependent on glucose as an energy source, with a protein called GLUT1 being highly active in the cancer. Elevated GLUT1 levels were also linked to other types of squamous cell cancers, including head and neck, esophageal, and cervical cancers.
Scientists have discovered novel driver mutations in lung cancer cells that may be responsive to targeted therapies and immunotherapy. The study identified 38 significantly mutated genes in lung adenocarcinoma and 20 in lung squamous cell carcinoma, with only 6 shared by both types.
A study by Genes and Cancer group at Bellvitge Biomedical Research Institute found that the inactivation of PARD3 gene promotes tumor cell invasion and metastasis in lung cancer. Restoring PARD3 levels significantly reduced the risk of metastasis in animal models.
Low preoperative serum squamous cell carcinoma antigen levels and absence of tumor invasion into the pleura or blood vessels are independent prognostic factors for patients with peripheral squamous cell carcinomas of the lung. These factors are associated with longer overall survival and reduced disease recurrence.
Researchers have developed a clinically relevant mouse model for squamous cell lung cancer, driven by the misregulation of genes sox2 and lkb1. The discovery uncovers new treatment strategies and provides insights into potential targeted therapies.
A study found that smokers with the BRCA2 gene defect are at an increased risk of developing lung cancer, with around one in four suffering from the disease. The researchers also discovered a link between squamous cell lung cancer and a defect in the CHEK2 gene.
Researchers have identified a new potential treatment for squamous cell lung cancer by targeting a specific protein called DDR2, which interacts with collagen to protect against cancer growth. The findings could lead to the development of targeted therapies for this previously untreatable form of lung cancer.
Researchers have identified several potential therapeutic targets for squamous cell lung cancer, including alterations in the TP53 and CDKN2A genes. These genetic changes may be susceptible to drug inhibition, providing new opportunities for clinical trials and potentially transforming treatment outcomes.
A nationwide consortium of scientists has reported a comprehensive genetic analysis of squamous cell carcinoma of the lung, revealing almost 75% of patients' cancers have targetable mutations. The research provides insight into the molecular biology of lung squamous cell carcinoma and identifies potential targets for therapies.
Researchers have characterized the lung squamous cell carcinoma genome, identifying commonly known cancer genes and mutations that could be targeted therapeutically. The study, led by UNC Lineberger scientists, paves the way for developing better, more targeted treatments for this devastating disease.
Researchers at Memorial Sloan Kettering Cancer Center have identified three genetic targets in approximately 50% of patients with squamous cell carcinomas. This breakthrough enables personalized treatment for a previously untreatable type of lung cancer.
A University of Colorado Cancer Center investigator has received a prestigious grant to develop targeted treatments for squamous cell lung cancer. The project aims to identify prognostic signatures and molecular targets for early-stage patients, paving the way for personalized cancer care.
Researchers found that fibrous stroma surrounding squamous cell carcinoma tumors was associated with reduced 5-year recurrence-free survival and overall survival rates. The study suggests that targeting the tumor microenvironment may be a meaningful approach for developing treatment strategies.
Researchers found a potential target for treating squamous cell lung cancer by identifying a DDR2 gene mutation that responds to dasatinib treatment. Approximately one in two thousand people in the US annually carry this mutation, and tumor cells with it showed significant response to dasatinib, indicating a new targeted therapy option.
A study has identified the BRF2 oncogene as specifically associated with lung squamous cell carcinoma, potentially serving as an identification marker and novel therapeutic target. Genetic analysis found frequent activation of BRF2 in pre-invasive stages of the disease, suggesting its role in tumorigenesis.
A new microRNA-based diagnostic test has been shown to identify squamous lung cancer with high accuracy, offering improved treatment options for patients. The test's 96% sensitivity and 90% specificity make it a promising tool in the fight against this aggressive form of cancer.
A team of scientists has developed a tissue-engineered, organotypic 3D culture system of esophageal squamous cell cancer, revealing the genetic mutations and tumor microenvironment driving the disease. The model also highlights the critical role of stromal fibroblasts in cancer progression.
Researchers have identified a critical gene, LKB1, that is mutated in almost a quarter of all human lung cancers, leading to more aggressive tumors. The study provides a new target for therapies and enables better patient prognoses.
Lilly Oncology will present data on three oncology agents, ALIMTA, GEMZAR, and enzastaurin, at the 43rd Annual Meeting of the American Society of Clinical Oncology. The company's studies focus on various types of cancer, including non-small cell lung cancer and breast cancer.
A new EGFR antibody shows promise in treating lung cancer by targeting activated receptors. In a mouse model, the antibody caused significant tumor regression where cetuximab failed.
Researchers have shown that smoking more than triples the risk of developing squamous cell carcinoma, a type of skin cancer. The study found that current smokers were three times more likely to develop the cancer compared to former smokers.